Set Point Acupuncture for Migraines Using a Digital Assistant (SPAMDA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Johnstown, Pennsylvania, United States, 15904
- John P Murtha Neuroscience and Pain Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects between the ages of 21 years and 65 years of age
- Subjects with a history of migraine headaches for at least 12 months
- Subjects who have not received acupuncture for any medical condition in the past 6 months.
- A negative pregnancy test for childbearing females since some acupuncture points may be contraindicated in pregnancy. Pregnancy tests will be conducted at MMC.
- Subjects willing and able to use a PDA daily for data collection
Exclusion Criteria:
- Subjects who plan to receive acupuncture treatment for any other type of medical condition while enrolled in this protocol
- Subjects with the presence of organic pathology (i.e., brain tumor)
- Subjects who have the presence of a systemic disorder or illness, including serious psychiatric illness
- Subjects who began a new headache treatment less than two weeks before proposed enrollment date
- Subjects who are pregnant, lactating, or planning to become pregnant within 6 months
- Subjects that use alcohol on a regular basis
- Subjects that use recreational drugs
- Subjects that have a cardiac pacemaker
- Subjects that use analgesics on more than 10 days per month
- Subjects that exercise prophylactic headache treatment with drugs during the past 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: 1
|
8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
If a standard set of acupuncture points delivered over a set time frame, reduces the frequency and intensity of headaches in a population of migraine sufferers.
Time Frame: 32 weeks
|
32 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measurements of the impact of acupuncture intervention will be detected when baseline measurements of frequency and severity of headaches is compared to measurements taken 12 weeks after the last acupuncture session. MIDAS, HIT-6, BDI-II and SF-12 scores
Time Frame: 32 weeks
|
32 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sharon Plank, MD, LAc, John P. Murtha Neuroscience and Pain Institute
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MMC 07-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.